Drug reference
bnt162b2
mRNA vaccine · vaccine
mRNA vaccinevaccine
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
BNT162b2 contains an mRNA encoding full-length SARS-CoV-2 spike protein, delivered in a lipid nanoparticle. Once injected, the nanoparticles are taken up by antigen-presenting cells (APCs) that subsequently express the spike protein, resulting in an immune response.
Indications
prevention of severe or fatal COVID-19
Dosing
- Adult
- injected in two doses, 21 days apart
Related guidelines
Other mRNA vaccine drugs
Ask House about bnt162b2
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team